|
 |
MaxipimeThis page contains recent news articles, when available, and an overview of Maxipime but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Maxipime (when available) Cefuroxime, a second-generation cephalosporin, is used to treat severe upper and lower respiratory tract infections, skin infections, otitis media, and surgical prophylaxis. For the treatment of the following infections (respiratory, skin, soft tissue, urinary tract infections, ear, nose, throat infectsion) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A ß-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph. Also used to treat acute bacterial bronchitis in patients with COPD Mechanism Of Action: Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor. News Articles on Cefuroxime Elan Swings To Profit In Q3 - Oct 21, 2009 Azactam revenue fell 18% to $19.8 million from $24.2 million in 2008, primarily due to supply shortages, while Maxipime revenue plunged 68% to $1.8 million ... RTT News REG-Elan Corporation PLC Elan Reports Third Quarter 2009 Financial Results - Oct 21, 2009 The increase was primarily due to solid growth in Tysabri sales, which more than compensated for reduced sales of Azactam and Maxipime. ... Reuters Elan Reports Third Quarter 2009 Financial Results - Oct 22, 2009 ...from the Biopharmaceuticals business was driven by a solid performance from Tysabri ® , more than offsetting reduced sales of Azactam ® and Maxipime ® . ... Business Wire (press release) Elan Corporation, plc - SWOT Analysis - Oct 23, 2009 Other marketed products in its portfolio include Prialt, Maxipime and Azactam. Elan is headquartered in Dublin, Ireland and employed 1610 people as of ... PRMinds (press release) Elan 虧æ??å°?æ–¼é ?期 - Oct 21, 2009 ...生物製藥收入æˆ?é•·ï¼Œæ˜¯å› Tysabri銷售æˆ?長，抵銷Azactam與Maxipime銷售的下跌。 Elançš„Tysabri銷售é¡?å¢žåŠ 16%，創新高é?”1.914憶美元，2008年第三å£ç‚º1.645憶美元。 ... 環球財經 Bristol-Myers, Elan's Maxipime Will Get US Review - Nov 14, 2007 By Beth Jinks. Nov. 14 (Bloomberg) -- Maxipime, an antibiotic marketed in the US by Elan Corp. and elsewhere by Bristol-Myers Squibb Co., is being reviewed ... Bloomberg Elan Q2 pretax loss widens on non-cash charge of 52.2 mln usd UPDATE - Jul 26, 2007 The company expects future revenues from Maxipime and its Azactam antibiotic to ... While the impact of a generic competitor to Maxipime, and the timing of ... Forbes Drugmaker Elan trims Q1 loss, holds revenue goal - Apr 24, 2008 Maxipime is facing growing generic competition after its patent expired last year and revenue from the drug dropped 81 percent versus a year earlier to ... Reuters Elan's Tysabri 'could be back by April' - Oct 27, 2005 There were increased sales of Maxipime and Azactam, while the figures also included sales of pain treatment Prialt, which was launched this year. ... RTE.ie Loss Narrows for Elan - Aug 1, 2006 Without Tysabri, Elan's revenue has come from other products, like its biggest seller Maxipime, an intravenous antibiotic for pneumonia and other bacterial ... TheStreet.com - TheStreet.com (subscription) Elan Third-Quarter Loss Widens as Maxipime Sales Slip - Oct 25, 2006 By Etain Lavelle. Oct. 25 (Bloomberg) -- Elan Corp., which reintroduced the Tysabri multiple sclerosis treatment in July, said its third- quarter loss ... Bloomberg Elan's Q3 losses worse than expected - Oct 25, 2006 Elan said this was as a result of lower revenues from its Maxipime drug due to ... Revenue from Maxipime was 22% lower than in the same quarter of 2005. ... RTE.ie FDA Recommends Caution Over Maxipime Risk - Nov 26, 2007 The FDA warned healthcare professionals to be cautious when prescribing Bristol-Myers Squibb's (BMS) broad-spectrum B-lactam antibiotic Maxipime after a ... FDA news - FDA news (subscription) The Irish Times - Thu, Jul 24, 2008 - Elan loss narrows on rising... - Jul 24, 2008 This had more than off-set a reduction in sale of its drug Maxipime due to generic competition, he said. "We remain on track to record adjusted EBITDA ... Irish Times The Irish Times - Thu, Aug 28, 2008 - Losses narrow at Elan as... - Aug 28, 2008 ...driven by strong growth in Tysabri which the company said more than compensated for reduced sales of its Maxipime drug due to generic competition. ... Irish Times Elan cuts underlying losses in Q2 - Jul 26, 2007 The $52m charge was linked to a writedown in the value of its assets as a result of the approval of a competitor to its Maxipime drug. ... RTE.ie Maxipime May Be Linked to Increased Risk for Death - Nov 15, 2007 November 15, 2007 — Cefepime HCl injection (Maxipime, Bristol-Myers Squibb Co) may be linked to an increased risk for death, the US Food and Drug ... Medscape Maxipime's expiry a cause for meltdown - Feb 14, 2008 The expiration of exclusive patent rights on Elan's Maxipime drug caused the virtual collapse of revenues from this source in the final quarter of 2007 and ... Irish Independent Q4 2004 Elan Corporation, PLC Earnings Conference Call - Part 2. - Feb 8, 2005 The bottom is split between Maxipime and Azactam and (inaudible) manufacturing royalties. COREY DAVIS: Okay, I will give someone else a chance. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com ELAN (ELA). - Feb 10, 2006 These were boosted by higher sales of intravenous antibiotics Maxipime and Azactam. For 2005 as a whole, Maxipime's revenues rose 19 per cent to $140m, ... Free with registration - Investors Chronicle - AccessMyLibrary.com First-Time Generic Approvals: Maxipime, Tessalon 200 mg, Vesanoid - Jun 29, 2007 June 29, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for cefepime hydrochloride 500 mg, 1 g, ... Medscape FDA Recommends Caution Over Maxipime Risk - Nov 16, 2007 The FDA warned healthcare professionals to be cautious when prescribing Bristol-Myers Squibb's (BMS) broad-spectrum B-lactam antibiotic Maxipime, ... FDA news - FDA news (subscription) Q4 2004 Elan Corporation, PLC Earnings Conference Call - Part 3. - Feb 8, 2005 Could you remind us of the strategic rationale for keeping Maxipime and Azactam ... On the Maxipime and Azactam, the way I would answer that is as follows. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Where Is Elan Going? - Apr 25, 2007 Its other top products, Maxipime and Azactam -- which accounted for more than 40% of its $176 million in revenue this quarter -- could be facing generic ... fool.com EDITED BRIEF - Apr 24, 2008 ...the lower Maxipime revenues due to the introduction of generic competition ... A generic form of Maxipime was approved in June 2007, and launched shortly ... $54.00 - Thomson StreetEvents - Alacra Store Texas Case Law - JELINEK v. CASAS, 13-06-00088-CV (Tex.App. [13th … - Jul 29, 2008 To treat the unidentified infection, Dr. Jelinek prescribed Maxipime, a broad-spectrum ... Maxipime, which is considered an effective treatment for E. coli, ... Pay-Per-View - Texas Case Law - Loislaw Elan Q4, FY net loss narrows; sees break-even adj EBITDA by 2007-end ... - Feb 20, 2007 It added that the basic US patent for Maxipime expires in March and two other US patents covering Maxipime formulations expire in February 2008. ... Forbes Event Brief of Q3 2006 Elan Corporation, PLC Earnings Conference Call... - Oct 25, 2006 Maxipime was supplied by BMS and had some difficulties in past with supply. 4. Supply has not resumed and will continue to monitor situation carefully. 3. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Chugai Launches Actemra for Castleman's Disease - Jun 27, 2005 Bristol-Myers Squibb KK launched Maxipime Bag 1 g for Drip Infusion (cefepime), a double-bag ... Compared to Maxipime Inj, the new product is easier to mix, ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones FINAL TRANSCRIPT - Apr 24, 2008 ...compensating for the lower Maxipime revenues due to the introduction of ... As you will recall, a generic form of Maxipime was approved in June 2007 and ... $54.00 - Thomson StreetEvents - Alacra Store Dictan formal prisión a distribuidores de medicamentos apócrifos - May 15, 2007 ...localizado en la ciudad de Morelia, Michoacán, le advirtió al encargado de ventas de Bristol Myers Squibb que el medicamento "Maxipime", fabricado por ... oem.com.mx Elan Reports Narrowed Loss - Oct 27, 2005 Elan previously noted supply disruptions with regard to Maxipime that led to dwindling customer inventories. In its third-quarter release, the company said: ... TheStreet.com - TheStreet.com (subscription) Revenue on the Rise at Elan - May 4, 2006 Sales from Maxipime more than doubled from last year to $44.7 million. Azactam sales were also more than twice last year's result, and rose to $19.9 million ... TheStreet.com - TheStreet.com (subscription) Elan Corporation, PLC at Morgan Stanley Pharmaceutical CEOs … - Jan 5, 2006 Our Maxipime, Azactam products -- Azactam is actually already generic or can ... Maxipime we have another almost two years. But again our goal would be to ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Finance; Neuroscience-based biotech cuts losses during "transitional"... - Mar 18, 2005 Maxipime prescription demand for the fourth quarter of 2004 increased by 16% compared to the same period in 2003 while revenues for the quarter decreased ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Finance; Neuroscience-based biotech cuts losses during "transitional"... - Mar 14, 2005 Maxipime prescription demand for the fourth quarter of 2004 increased by 16% compared to the same period in 2003 while revenues for the quarter decreased ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Detectan en Morelia medicina "pirata" - Feb 25, 2008 Fue en noviembre de 2006 cuando la PGR detectó esta organización criminal al decomisarle 11 toneladas de medicamentos apócrifos y caducos de nombre Maxipime ... oem.com.mx Tysabri still the key to improving Elan - May 11, 2006 Elan recently released better-than-expected results for the first quarter after the company narrowed losses and grew sales of its antibiotic Maxipime. ... unison.ie Cephalosporins (Systemic). - Aug 1, 2006 Kefurox(19) Kefzol(4) Mandol(3) Maxipime(6) Mefoxin(12) Monocid(8) Omnicef(5) Rocephin(18) Tazicef(15) Tazidime(15) Vantin(13) Velosef(23) Zinacef(19) ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Moody's Cuts Credit Outlook on Elan - Mar 1, 2005 Moody's pointed out that two key Elan products -- the antibiotics Azactam and Maxipime -- will lose patent protection in 2006 and 2008, respectively. ... TheStreet.com - TheStreet.com (subscription) The Antibacterial Drug Market Analysis 2008-2013 - Mar 19, 2008 Maxipime. 4.3. Rocephin Will Decline in Growth ... Maxipime Sales Will be Affected by the Loss of. Patent Protection ... $4,356.00 - VISIONGAIN A - Alacra Store Elan narrows losses in 2004, looks to profitability by end-2006;... - Feb 14, 2005 This comprised sales of the firm's two antibiotics, Maxipime (cefepime) and ... However, for the fourth quarter, Maxipime turnover dipped 4.1% to $29.9 ... $4.95 - Pharma Marketletter - ECNext ELN, FOXH, XCYT, IDSA, GNBT, BKHM have been on BUYINS.NET … - May 26, 2005 MAXIPIME for Injection is a semi-synthetic, broad-spectrum, cephalosporin antibiotic used by pulmonologists, infectious disease specialists, ... $4.95 - M2 Presswire - ECNext Retiran 40 millones de medicamentos apócrifos - Jun 23, 2007 En este nosocomio, en octubre de 2005 se detectó la ineficacia del medicamento Maxipime, prescrito como parte del tratamiento para niños con cáncer. ... El Universal - El Universal (México) ELN, GNBT, IDSA, FOXH, XCYT, GOL Have Been Added To Naked Short … - May 10, 2005 MAXIPIME for Injection is a semi-synthetic, broad-spectrum, cephalosporin antibiotic used by pulmonologists, infectious disease specialists, ... $4.95 - M2 Presswire - ECNext Los productores de genéricos aprovechan un vacÃo de información para ... - Aug 8, 2007 Otro caso es el de Bristol-Myers Squibb quien cuenta con la patente de principio activo de Cefepima, el ingrediente principal del antibiótico Maxipime, ... Reforma - Reforma (Suscripción) Press Release: ELN, FOXH, XCYT, IDSA, GNBT, BKHM have been on … - May 26, 2005 MAXIPIME for Injection is a semi-synthetic, broad-spectrum, cephalosporin antibiotic used by pulmonologists, infectious disease specialists, ... Pay-Per-View - M2 Presswire - HighBeam Research Elan FY pretax loss widens to 398.1 mln usd, 2008 revenues seen up 30... - Feb 13, 2008 ...on the inclusion of charges in 2007 related to the introduction of a generic competitor to its pneumonia treatment Maxipime, the consolidation of its ... Forbes Elan 'optimistic' on Tysabri return, earmarks cash for relaunch UPDATE - Jan 31, 2006 Rising revenues from Elan's core products, including antibacterial drug Maxipime and antibiotic Azactam, and flat research and selling expenses have helped ... Forbes L'antibiotico Cefepime associato ad un aumento della mortalità - Jan 24, 2008 Cefepime ( Maxipime ) è una cefalosporina ad ampio spettro, approvata per il ... Bristol-Myers Squibb, la società produttrice di Maxipime, sta collaborando ... XagenaSalute Elan Shares Discounting $1.2B Tysabri Sales - Feb 1, 2006 Elan attributed the earnings beat to better-than-expects sales of Maxipime and Azactam, along with lower research costs. "It has been a difficult 2005, ... Forbes Sharewatch: Elan needs a booster jab - Oct 22, 2006 ...to post a 16% increase in sales to $142.9m (€113.3m), helped by the first-time contribution of Tysabri and soaring sales for its antibiotic Maxipime. ... Times Online THE INVESTMENT COLUMN: Elan tries to put the past behind it - Feb 9, 2005 It has sales from prescription jabs Azactam and Maxipime for pneumonia and other infections, and income from contract manufacturing for other drug companies ... Independent Incautadas 40 millones de dosis de medicina "pirata" - Jul 8, 2007 Fue en noviembre de 2006 cuando la PGR detectó esta organización criminal, al decomisarles 11 toneladas de medicamentos apócrifos y caducos de "Maxipime". ... oem.com.mx Medicamentos “pirataâ€?, peligro para los hospitales - Jun 25, 2007 En este hospital, en octubre de 2005 se detectó la dudosa calidad del medicamento conocido como “Maxipimeâ€?, que se suministra como parte del tratamiento de ... El Siglo de Torreón Elan pain drug sells below expectations - Oct 30, 2005 ...while Maxipime, another antiobiotic and Elan's current top-selling drug with sales last year of $117.5m, sees its patent expire in 2008. ... Times Online APP Pharmaceuticals Launches Cefepime Hydrochloride for - Mar 25, 2008 ...today announced that it has launched Cefepime Hydrochloride for Injection, the generic equivalent of Maxipime(R) marketed by Elan Corporation, plc. ... Bloomberg Article: Drug's return aids Elan Telephone stocks fall as executives ... - Feb 1, 2006 Elan said its fourth-quarter loss narrowed, helped by its manufacturing business and injectable antibiotic Maxipime.Svenska Cellulosa, Europe's biggest ... Pay-Per-View - International Herald Tribune - HighBeam Research Loss Narrows for Elan - Feb 20, 2007 Among other products, fourth-quarter sales of the intravenous antibiotic Maxipime fell to $46.2 from $46.8 million for the same period in 2005. ... TheStreet.com - TheStreet.com (subscription) ELN - Elan Corp PLC Company Profile - CNNMoney.com - Dec 12, 2008 Azactam and Maxipime are designed to address medical needs within the hospital environment. The Company's biopharmaceutical pipeline includes a range of ... CNNMoney.com Will FDA put humans at risk with cow drug? - Mar 4, 2007 Only one medicine from that family has been approved in the United States, a powerful drug for humans, cefepime (brand name Maxipime), which is the only ... Seattle Times Elan Tysabri hopes as losses narrow - Aug 1, 2006 Product revenue was up 17% to $130.8m, with Maxipime and Azactam sales growing strongly. Sales of pain treatment Prialt, launched in the US last year, ... RTE.ie FDA still reviewing cefepime safety risk - May 14, 2008 ...was reviewing safety data that raised concerns about a potential increased mortality in patients treated with the drug, which is marketed as Maxipime. ... United Press International Meltdown on bourses as credit crunch bitesEUROPEMARKETPLACE by … - Jul 27, 2007 Elan, the largest Irish drug maker, declined, saying that its second-quarter loss had widened as the company wrote down the value of the Maxipime antibiotic ... Pay-Per-View - International Herald Tribune - HighBeam Research Elan's Q1 losses deepen on Tysabri suspension - Apr 28, 2005 However, some of the gains were offset by lower sales of Maxipime and Azactam. Elan said its contract manufacturing and royalty revenue was $43.5m in the ... RTE.ie UK's FTSE 100 Index Rises; Tate & Lyle Gains on Possible Sale - Oct 25, 2006 ...loss widened to $117 million from $67.1 million a year earlier on lower sales of the antibiotic Maxipime and increased administrative costs. Bloomberg Elan exit from SD is part of makeover - Aug 4, 2007 A major portion of the loss was related to the one-time write down of Maxipime, a pneumonia drug that Elan acquired with Dura, after the US Food and Drug ... San Diego Union - Tribune - San Diego Union Tribune European Stocks Decline, Led by Credit Suisse, Axa, Atos Origin - Jul 26, 2007 Ireland's largest drugmaker said its second-quarter loss widened as the company wrote down the value of the Maxipime antibiotic because of generic ... Bloomberg UK Stocks Decline, Led by Legal & General, Home Retail Falls - Jul 26, 2007 Ireland's biggest drugmaker reported a second-quarter net loss that widened to $141.1 million as the company wrote down the value of the Maxipime antibiotic ... Bloomberg UK Stocks Decline, Paced by Vodafone, BHP; Ryanair Slumps - Aug 1, 2006 Ireland's biggest drugmaker said its second-quarter loss shrank to $90.5 million from $142.4 million on sales of the antibiotic Maxipime and contract ... Bloomberg Doctor rates his drug rep gifts online - Feb 2, 2007 Sought after items include Zetia calipers, a Diovan penlight, Maxipime scissors and a Toprol tool set that includes a mini Swiss Army knife. ... 6minutes Infineon, Munich Re, Pernod, Wincor: European Equity Preview - Jan 28, 2007 The company in October said its third-quarter loss widened on lower sales of the antibiotic Maxipime and increased administrative costs. ... Bloomberg Elan's break-even date pushed back to 2008 - Jul 27, 2007 ...said yesterday the decision to push out the date to next year was due to earlier than anticipated competition for its pneumonia treatment, Maxipime. ... Irish Independent Biogen/Elan's Tysabri adds pressure on FDA - Mar 6, 2005 Elan has three other products, Maxipime, Prialt and Azactam, on the market and receives royalties on several others. In related news, proceedings by the ... finfacts.com FDA Approves Cattle Antibiotic Despite Concerns - Mar 6, 2007 This new powerful antibiotic for cattle, cefquinome, is very similar to the antibiotic cefepime [Maxipime] which is used as a last ditch effort when other ... OhmyNews International Indagan venta de medicamentos controlados caducos en farmacias - Oct 28, 2007 Este fue el caso de tres menores enfermos de cáncer, a quienes se les suministró el medicamento Maxipime en el hospital infantil Eva Sámano de López Mateos, ... El Universal - El Universal (México) Lekarstwa na cenzurowanym - Feb 1, 2005 Kilka dni temu wstrzymano sprzedaż czterech preparatów wÅ‚oskiej firmy BMS - antybiotyków Azactam, Duracef, Maxipime i Cefzil. ... NaszeMiasto.pl Uważaj na Duracef! - WiadomoÅ›ci - Biznes w INTERIA.PL - gieÅ‚da, … - Jan 24, 2005 Główny Inspektor Farmaceutyczny wstrzymaÅ‚ dystrybucjÄ™ Azactamu, Maxipime, Cefzilu oraz bardzo popularnego antybiotyku Duracef. Wszystkie leki sÄ… produkowane ... Interia Elan Corp. plc Added to Bellwether Watch List. - Feb 21, 2007 Its current offerings include anti-infectives Maxipime and Azactam. The company in 2005 temporarily yanked from the market multiple sclerosis therapy ... Free with registration - M2 Presswire - AccessMyLibrary.com Daily Market Alert for Elan Corp. plc. - Apr 24, 2007 Its current offerings include anti-infectives Maxipime and Azactam. Elan's future fortunes rely largely on the success of beleaguered multiple sclerosis ... Free with registration - M2 Presswire - AccessMyLibrary.com Tysabri sales improve Elan's 2nd-qtr loss 49%. - Aug 4, 2008 ...primarily related to the introduction of generics of the antibiotic Maxipime (cefepine) and the consolidation of Elan's activities on the US west coast. ... $9.94 - Pharma Marketletter - Alacra Store Losses widen, sales dip at Elan despite rollout of key MS drug... - Oct 25, 2006 ...temporary supply problems for its injected antibiotic Maxipime; the US$23 million (A18.3 million) sale in 2005 of a drug called Zonegran; and changes in ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Morning Alert for Elan Corp. plc. - May 4, 2007 Maxipime, an injectable cephalosporin antibiotic to treat serious and/or life-threatening infections, such as pneumonia, urinary tract infection, ... Free with registration - M2 Presswire - AccessMyLibrary.com Elan Corp. plc is Added to Watch List. - Mar 20, 2007 Its current offerings include anti-infectives Maxipime and Azactam. Elan's future fortunes rely largely on the success of beleaguered multiple sclerosis ... Free with registration - M2 Presswire - AccessMyLibrary.com Shareholders alert for Elan Corp. plc. - May 21, 2007 Maxipime, an injectable cephalosporin antibiotic to treat serious and/or life-threatening infections, such as pneumonia, urinary tract infection, ... $4.95 - M2 Presswire - ECNext Current Research on Elan Corp. plc. - Apr 3, 2007 Maxipime, an injectable cephalosporin antibiotic to treat serious and/or life-threatening infections, such as pneumonia, urinary tract infection, ... Free with registration - M2 Presswire - AccessMyLibrary.com Elan Corporation, PLC at JPMorgan 25th Annual Healthcare Conference … - Jan 9, 2007 And going forward, Azactam is off patent but we haven't seen a competitive product coming to the market yet, Maxipime has patent protection until the middle ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Losses at Elan improve to $384m and shares rise. - Feb 1, 2006 A breakdown of last year's sales showed they were boosted by strong growth for Maxipime and Azactam, while its new pain treatment, Prialt, recorded sales of ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Elan to strip out 100 mln usd of costs following Tysabri withdrawal … - Apr 28, 2005 Maxipime revenue was impacted by supply shortages, falling to 19.8 mln usd from 28.2 mln, while Azactam fell to 8.4 mln usd from 13.8. ... Interactive Investor ALSO NOTED: FDA panel to mull Celebrex safety for kids; Sanofi makes ... - Mar 25, 2008 Sagent Pharmaceuticals launched its injectable form of Cefepime, a broad spectrum antibiotic that is the copycat form of Elan's Maxipime. Release ... FiercePharma Research and Markets: Tysabri is Expected to be the Main Growth... - Nov 22, 2007 The company currently markets anti-infectives Maxipime and Azactam, as well as Tysabri, its landmark product co-developed with Biogen Idec. ... Free with registration - Business Wire - AccessMyLibrary.com Elan's 4th-qtr loss down 55%.(Financial report) - Mar 5, 2007 The Dublin-headquartered company also reported that its turnover for the fourth quarter increased 19% to $166.4 million, with its antibiotic Maxipime ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Elan sees 3rd-qtr loss narrow, sales rise 43%.(Financial report) - Nov 12, 2007 Other products in Elan's portfolio include: the antibiotic Maxipime (cefepine), which saw turnover rise 27% to $19.2 million; Azactam (aztreonam for ... Free with registration - Pharma Marketletter - AccessMyLibrary.com India top drug tweaker again - Aug 16, 2006 The patents of both Omnicef ($650 million brand, cefdinir) and Maxipime ($150-million, cefepime) will be expired in 2007. Aurobindo also filed for ... Daily News & Analysis Dueling Fools: Elan Bear - Mar 15, 2007 ...sales that will mostly disappear in the next two years as Elan loses patent protection on its top two other marketed products, Maxipime and Azactam. ... fool.com FDA still reviewing cefepime safety risk - May 15, 2008 ...was reviewing safety data that raised concerns about a potential increased mortality in patients treated with the drug, which is marketed as Maxipime. ... Money Times - The Money Times Also in Business - Oct 20, 2007 Azactam, which is used in the treatment of urinary and respiratory infections, Maxipime, which is used to treat pneumonia and abdominal infections, ... Irish Independent Elan reports 2007 net loss of $405.0 million; Revenues forecast to... - Feb 13, 2008 ...higher than in 2006 mainly due to the inclusion of $103.4 million in charges in 2007 related to the introduction of a generic competitor to Maxipime, ... FinFacts Ireland Transave, Inc. Appoints Renu Gupta, MD Chief Medical Officer. - Oct 5, 2006 ...where she was involved in the development and approval of such leading drugs as Abelcet(R), Cefzil(R), Maxipime(R), Videx(R), and Diovan(R). ... Free with registration - PR Newswire - AccessMyLibrary.com First-time generic, approvals.(FDA Drug Approvals)(Brief article) - Sep 1, 2007 ...injection (equiv to Cefotan [discontinued]) ABRAXIS Cefepime for injection, 500 mg/ vial, 1 g/vial, and 2 g/vial (equiv to Maxipime for injection) ORCHID. Free with registration - Formulary - AccessMyLibrary.com Screening the antioxidant and antimicrobial properties of the lichens... - Jul 1, 2006 Maxipime (Bristol-Myers Squibb) at a concentration range of 500-7.8 [micro]g/ml was prepared in nutrient broth and used as standard drug for positive ... Free with registration - Phytomedicine: International Journal of... - AccessMyLibrary.com Trading Alert for Elan Corp. plc. - Jan 8, 2007 Its current offerings include anti-infectives Maxipime and Azactam. The company in 2005 temporarily yanked from the market multiple sclerosis therapy ... $4.95 - M2 Presswire - ECNext In- Depth Research on Elan Corp. plc. - May 25, 2007 Maxipime, an injectable cephalosporin antibiotic to treat serious and/or life-threatening infections, such as pneumonia, urinary tract infection, ... $4.95 - M2 Presswire - ECNext Top 50 packagers: pharmaceutical.(TOP 200 PACKAGERS)(Company … - Jul 1, 2007 Corp.plc Tysabri; Prialt; 1 Dublin, Ireland / Maxipime; Azactam South San Francisco, Calif. 50 Amylin Pharmaceuticals Byetta; Symlin 1 San Diego, Calif. ... Free with registration - Food & Drug Packaging - AccessMyLibrary.com Press Release: Tysabri is Expected to be the Main Growth Driver of … - Nov 21, 2007 The company currently markets anti-infectives Maxipime and Azactam, as well as Tysabri, its landmark product co-developed with Biogen Idec. ... Pay-Per-View - M2 Presswire - HighBeam Research Brand Names/Synonyms: Maxipime is also known by the following brand names and/or synonymsAncef; Biofuroksym; Ceclor; Ceclor Cd; Cedax; Cefditoren; Cefizox; Cefotan; Ceftin; Ceftizoxime Sodium; Cefurax; Cefuril; Cefuroxim; Cefuroxime; Cefuroxime Axetil; Cefuroxime Free Acid; Cefuroxime Sodium; Cefuroxime Sodium Salt; Cefuroxime [Usan:Ban:Inn]; Cefuroxime and Dextrose in Duplex Container; Cefuroximo [Inn-Spanish]; Cefuroximum [Inn-Latin]; Cefzil; Cephuroxime; Ceptaz; Duricef; Elobact; Fortaz; Keflex; Keftab; Kefurox; Kefurox in Plastic Container; Kerurox; Mandol; Maxipime; Mefoxin; Monocid; Omnicef; Oraxim; Rocephin; Sharox; Tazicef; Vantin; Velosef; Zinacef; Zinacef Danmark; Zinacef in Plastic Container; Zinat; Zinnat Drug Category: Maxipime is categorized under the following by the FDA: Anti-bacterial Agents; Cephalosporins; ATC:J01DC02 Dosage Forms: POWDER; POWDER FOR SOLUTION; TABLET Absorption: Well absorbed from the GI tract (bioavailability is 37-52%) Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 4-(carbamoyloxymethyl)-8-[2-(2-furyl)-2-methoxyimino-acetyl]amino-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |